Neurotech International Ltd (ASX: NTI) Share Price and News
Price
$0.017
Movement
0.00 (0.0)
as at 16 Jun 10:06am (20 mins delayed)
52 Week Range
$0.017 - $0.093
1 Year Return
-72.13%
Neurotech International Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$17.84 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.05 billion
Earnings per share
-0.012
Dividend per share
N/A
Year To Date Return
-69.09%
Earnings Yield
N/A
Franking
-
Share Price
$0.017
Day Change
0.00 (0.0)
52 Week Range
$0.017 - $0.093
Yesterday's Close
$0.017
Today's Open
$0.017
Days Range
$0.017 - $0.017
Volume
194,205
Avg. Volume (1 month)
539,911
Turnover
$3,301
as at 16 Jun 10:06am
Neurotech International Ltd (ASX: NTI)
Latest News
No posts found.
NTI ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| 16th Jun 2025 2025-06-16T08:59:09 | NTI Appoints Dr. Bonni Goldstein as Chief Medical Advisor | YesNo | 8:59am | 2 | 130k |
| 6th Jun 2025 2025-06-06T08:57:55 | NTI164 to be presented at IRSF Annual Scientific Meeting | YesNo | 8:57am | 2 | 102k |
| 2nd Jun 2025 2025-06-02T09:19:51 | Positive Human PK Study Results for NTI164 | YesNo | 9:19am | 3 | 126k |
| 5th May 2025 2025-05-05T09:51:45 | NTI164 Preclinical Toxicology Studies Update | YesNo | 9:51am | 2 | 116k |
| 28th Apr 2025 2025-04-28T09:10:40 | Quarterly Activities/Appendix 4C Cash Flow Report | YesNo | 9:10am | 8 | 322k |
| 16th Apr 2025 2025-04-16T11:11:17 | Updated Trading Policy | YesNo | 11:11am | 6 | 170k |
| 2nd Apr 2025 2025-04-02T18:20:14 | Secondary Trading Notice | YesNo | 6:20pm | 1 | 89k |
| 2nd Apr 2025 2025-04-02T18:15:19 | Application for quotation of securities - NTI | YesNo | 6:15pm | 6 | 16k |
| 2nd Apr 2025 2025-04-02T18:12:54 | Final Director's Interest Notice | YesNo | 6:12pm | 2 | 156k |
| 1st Apr 2025 2025-04-01T16:20:22 | Resignation of Executive Director | YesNo | 4:20pm | 1 | 104k |
About Neurotech International Ltd
Neurotech International Ltd is a medical device and solutions company conducting clinical studies to assess the neuroprotective, anti-inflammatory, and neuro-modulatory activities of its proprietary cannabis strains. Geographically, all the firm's business activities function through the region of Australia. It operates in one segment: Medical Device Development and Distribution.
NTI Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Jun 2025 | $0.02 | $0.00 | 0.00% | 555,196 | $0.02 | $0.02 | $0.02 |
| 12 Jun 2025 | $0.02 | $0.00 | 0.00% | 857,647 | $0.02 | $0.02 | $0.02 |
| 11 Jun 2025 | $0.02 | $0.00 | 0.00% | 497,562 | $0.02 | $0.02 | $0.02 |
| 10 Jun 2025 | $0.02 | $0.00 | 0.00% | 861,119 | $0.02 | $0.02 | $0.02 |
| 06 Jun 2025 | $0.02 | $0.00 | 0.00% | 15,000 | $0.02 | $0.02 | $0.02 |
| 05 Jun 2025 | $0.02 | $0.00 | 0.00% | 354,330 | $0.02 | $0.02 | $0.02 |
| 04 Jun 2025 | $0.02 | $0.00 | 0.00% | 313,648 | $0.02 | $0.02 | $0.02 |
| 03 Jun 2025 | $0.02 | $0.00 | 0.00% | 1,261,973 | $0.02 | $0.02 | $0.02 |
| 02 Jun 2025 | $0.02 | $0.00 | 0.00% | 1,281,207 | $0.02 | $0.02 | $0.02 |
| 30 May 2025 | $0.02 | $0.00 | 0.00% | 711,906 | $0.02 | $0.02 | $0.02 |
| 29 May 2025 | $0.02 | $0.00 | 0.00% | 834,662 | $0.02 | $0.02 | $0.02 |
| 28 May 2025 | $0.02 | $0.00 | 0.00% | 882,304 | $0.02 | $0.02 | $0.02 |
| 27 May 2025 | $0.02 | $0.00 | 0.00% | 8,695 | $0.02 | $0.02 | $0.02 |
| 26 May 2025 | $0.02 | $0.00 | 0.00% | 130,158 | $0.02 | $0.02 | $0.02 |
| 22 May 2025 | $0.02 | $0.00 | 0.00% | 1,267,332 | $0.02 | $0.02 | $0.02 |
| 21 May 2025 | $0.02 | $0.00 | 0.00% | 60,165 | $0.02 | $0.02 | $0.02 |
| 20 May 2025 | $0.02 | $0.00 | 0.00% | 464,353 | $0.02 | $0.02 | $0.02 |
| 19 May 2025 | $0.02 | $0.00 | 0.00% | 114,921 | $0.03 | $0.03 | $0.02 |
| 16 May 2025 | $0.02 | $0.00 | 0.00% | 326,044 | $0.02 | $0.03 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 24 Feb 2025 | Anthony Filippis | Issued | 20,000,000 | $800,000 |
Issue of options.
|
| 03 Dec 2024 | Robert (Max) Johnston | Buy | 200,000 | $13,275 |
On-market trade.
|
| 20 Sep 2024 | Robert (Max) Johnston | Issued | 1,000,000 | $60,000 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Robert (Max) Maxwell Johnston | Non-Executive Director | Apr 2024 |
Mr Johnston held the position of President and Chief Executive officer of Johnson and Johnson Pacific, a division of the healthcare company for 11 years. Prior to this appointment, his career included several positions within Johnson and Johnson, both within Australia and overseas encompassing Europe and Asia. Mr Johnston's career also included senior roles within Australia and overseas with Unilever and Guinness-United Distillers and several prominent industry body roles as past President of ACCORD Australasia Limited, Vice Chairman of AFGC, and Board Member of ASMI.
|
| Mr Mark Davies | Non-Executive DirectorNon-Executive Chairman | Apr 2019 |
Mr Davies has over 20 years of experience in trading, investment banking and providing corporate advice. He worked at Montagu Stockbrokers before co-founding investment banking firm Cygnet Capital and more recently 1861 Capital. Mark specializes in providing corporate advice and capital raising services to emerging companies seeking business development opportunities and funding from the Australian market.
|
| Mr Gerald Quigley | Non-Executive DirectorDirector of Public Relations | Jul 2022 |
Mr Quigley is a Pharmacist and consumer health commentator. As a media health commentator heard each week on television and radio stations across Australia. He has knowledge relating to pharmaceutical and nutraceutical product development, dispensing & marketing in addition to product positioning within the relevant regulatory landscapes (e.g. TGA, FDA)
|
| Mr Anthony Filippis | Non-Executive Director | Feb 2025 |
--
|
| Ms Alessandra Gauvin | Company Secretary | Mar 2024 |
-
|
| Alexandra Andrews | Chief Operation Officer |
-
|
|
| Alessandra Gauvin | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| J & J Bandy Nominees Pty Ltd <Bandy P/F A/C> | 41,796,178 | 4.11% |
| Jalaver Pty Ltd <Falcon Pension A/C> | 40,268,347 | 3.96% |
| Dutch Ink (2010) Pty Ltd | 37,000,000 | 3.64% |
| Dutch Ink (2010) Pty Ltd i | 33,897,522 | 3.33% |
| The Trust Company (Australia) Limited <MOF A/C> | 30,506,500 | 3.00% |
| Chincherinchee Nominees Pty Ltd | 27,693,572 | 2.72% |
| The Trust Company (Australia) Limited <MBF A/C> | 26,850,255 | 2.64% |
| Gleneagle Securities Nominees Pty Limited | 26,829,185 | 2.64% |
| Citicorp Nominees Pty Limited | 26,781,993 | 2.63% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 25,013,360 | 2.46% |
| Mrs Melanie Therese Verheggen | 18,017,328 | 1.77% |
| MB Investment Capital Pty Ltd | 17,084,226 | 1.68% |
| Gofour Sail Pty Ltd | 17,073,000 | 1.68% |
| Quadrangle Capital Pty Ltd | 14,000,000 | 1.38% |
| Mr Vedat Isikgel | 12,649,999 | 1.24% |
| Mr Patrick Pasquale Steve Calabria <Dolce Elite A/C> | 12,000,000 | 1.18% |
| Buttonwood Nominees Pty Ltd | 11,525,396 | 1.13% |
| Max Cap Investments Pty Ltd | 11,080,000 | 1.09% |
| The Sun W Investment Pty Ltd <Sun Family A/C> | 11,027,272 | 1.08% |
| J & J Bandy Nominees Pty Ltd <J & J Bandy Super Fund A/C> | 9,500,000 | 0.93% |